Cargando…

Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity

[Image: see text] Naturally derived chemical compounds are the foundation of much of our pharmacopeia, especially in antiproliferative and anti-infective drug classes. Here, we report that a naturally derived molecule called carmaphycin B is a potent inhibitor against both the asexual and sexual blo...

Descripción completa

Detalles Bibliográficos
Autores principales: LaMonte, Gregory M., Almaliti, Jehad, Bibo-Verdugo, Betsaida, Keller, Lena, Zou, Bing Yu, Yang, Jennifer, Antonova-Koch, Yevgeniya, Orjuela-Sanchez, Pamela, Boyle, Colleen A., Vigil, Edgar, Wang, Lawrence, Goldgof, Gregory M., Gerwick, Lena, O’Donoghue, Anthony J., Winzeler, Elizabeth A., Gerwick, William H., Ottilie, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554889/
https://www.ncbi.nlm.nih.gov/pubmed/28696697
http://dx.doi.org/10.1021/acs.jmedchem.7b00671
_version_ 1783256855390191616
author LaMonte, Gregory M.
Almaliti, Jehad
Bibo-Verdugo, Betsaida
Keller, Lena
Zou, Bing Yu
Yang, Jennifer
Antonova-Koch, Yevgeniya
Orjuela-Sanchez, Pamela
Boyle, Colleen A.
Vigil, Edgar
Wang, Lawrence
Goldgof, Gregory M.
Gerwick, Lena
O’Donoghue, Anthony J.
Winzeler, Elizabeth A.
Gerwick, William H.
Ottilie, Sabine
author_facet LaMonte, Gregory M.
Almaliti, Jehad
Bibo-Verdugo, Betsaida
Keller, Lena
Zou, Bing Yu
Yang, Jennifer
Antonova-Koch, Yevgeniya
Orjuela-Sanchez, Pamela
Boyle, Colleen A.
Vigil, Edgar
Wang, Lawrence
Goldgof, Gregory M.
Gerwick, Lena
O’Donoghue, Anthony J.
Winzeler, Elizabeth A.
Gerwick, William H.
Ottilie, Sabine
author_sort LaMonte, Gregory M.
collection PubMed
description [Image: see text] Naturally derived chemical compounds are the foundation of much of our pharmacopeia, especially in antiproliferative and anti-infective drug classes. Here, we report that a naturally derived molecule called carmaphycin B is a potent inhibitor against both the asexual and sexual blood stages of malaria infection. Using a combination of in silico molecular docking and in vitro directed evolution in a well-characterized drug-sensitive yeast model, we determined that these compounds target the β5 subunit of the proteasome. These studies were validated using in vitro inhibition assays with proteasomes isolated from Plasmodium falciparum. As carmaphycin B is toxic to mammalian cells, we synthesized a series of chemical analogs that reduce host cell toxicity while maintaining blood-stage and gametocytocidal antimalarial activity and proteasome inhibition. This study describes a promising new class of antimalarial compound based on the carmaphycin B scaffold, as well as several chemical structural features that serve to enhance antimalarial specificity.
format Online
Article
Text
id pubmed-5554889
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-55548892017-08-15 Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity LaMonte, Gregory M. Almaliti, Jehad Bibo-Verdugo, Betsaida Keller, Lena Zou, Bing Yu Yang, Jennifer Antonova-Koch, Yevgeniya Orjuela-Sanchez, Pamela Boyle, Colleen A. Vigil, Edgar Wang, Lawrence Goldgof, Gregory M. Gerwick, Lena O’Donoghue, Anthony J. Winzeler, Elizabeth A. Gerwick, William H. Ottilie, Sabine J Med Chem [Image: see text] Naturally derived chemical compounds are the foundation of much of our pharmacopeia, especially in antiproliferative and anti-infective drug classes. Here, we report that a naturally derived molecule called carmaphycin B is a potent inhibitor against both the asexual and sexual blood stages of malaria infection. Using a combination of in silico molecular docking and in vitro directed evolution in a well-characterized drug-sensitive yeast model, we determined that these compounds target the β5 subunit of the proteasome. These studies were validated using in vitro inhibition assays with proteasomes isolated from Plasmodium falciparum. As carmaphycin B is toxic to mammalian cells, we synthesized a series of chemical analogs that reduce host cell toxicity while maintaining blood-stage and gametocytocidal antimalarial activity and proteasome inhibition. This study describes a promising new class of antimalarial compound based on the carmaphycin B scaffold, as well as several chemical structural features that serve to enhance antimalarial specificity. American Chemical Society 2017-07-11 2017-08-10 /pmc/articles/PMC5554889/ /pubmed/28696697 http://dx.doi.org/10.1021/acs.jmedchem.7b00671 Text en Copyright © 2017 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
spellingShingle LaMonte, Gregory M.
Almaliti, Jehad
Bibo-Verdugo, Betsaida
Keller, Lena
Zou, Bing Yu
Yang, Jennifer
Antonova-Koch, Yevgeniya
Orjuela-Sanchez, Pamela
Boyle, Colleen A.
Vigil, Edgar
Wang, Lawrence
Goldgof, Gregory M.
Gerwick, Lena
O’Donoghue, Anthony J.
Winzeler, Elizabeth A.
Gerwick, William H.
Ottilie, Sabine
Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity
title Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity
title_full Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity
title_fullStr Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity
title_full_unstemmed Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity
title_short Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity
title_sort development of a potent inhibitor of the plasmodium proteasome with reduced mammalian toxicity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554889/
https://www.ncbi.nlm.nih.gov/pubmed/28696697
http://dx.doi.org/10.1021/acs.jmedchem.7b00671
work_keys_str_mv AT lamontegregorym developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT almalitijehad developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT biboverdugobetsaida developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT kellerlena developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT zoubingyu developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT yangjennifer developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT antonovakochyevgeniya developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT orjuelasanchezpamela developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT boylecolleena developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT vigiledgar developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT wanglawrence developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT goldgofgregorym developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT gerwicklena developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT odonoghueanthonyj developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT winzelerelizabetha developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT gerwickwilliamh developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity
AT ottiliesabine developmentofapotentinhibitoroftheplasmodiumproteasomewithreducedmammaliantoxicity